

Introducing biology into clinics within PCM

A G E N D A

9TH NOVEMBER

| TIME | TOPIC | PRESENTER |
|---------------|---|--|
| 11:00 | Welcome by G. Vassal | |
| 11:00 – 13:00 | Clinical Sequencing Programs <i>Session Chairs: B. Geoerger / S. Pfister</i> ZERO Childhood Cancer Program Danish childhood cancer initiative DCCI Update on INFORM and MAPPYACTS Update on iTHER and SM-PAEDS What's after profiling? AcSé-ESMART and other targeting trials | M. Haber K. Nysom/M. Rossing or O. Oestrup D. Jones/G. Schleiermacher J. Molenaar/L. Chesler B. Geoerger |
| 13:00 – 14:00 | Lunch | |
| 14:00 – 14:30 | Clinical Sequencing Programs (cont'd) <i>Session Chairs: M. Casanova / F. Doz</i> Genetic predisposition | L. Brugières/C. Kratz |
| 14:30 – 14:45 | ITCC-P4 preclinical drug testing platform | S. Pfister |
| 14:45 – 16:00 | Cell cycle, apoptosis and metabolics <i>Session Chair: P. Kearns</i> CDK4/6: did we bet on the wrong CDKs? From CDK4/6 to CDK2/CDK9i? Venetoclax BCL2 ITCC-068 Enasidenib (AG-221) ITCC-057 – ESMART Arm I Arginase BCT-100 PARC ITCC-062 | F. Bautista/L. Marshall J. Vormoor S. Ducassou F. Mussai |
| 16:05 – 16:25 | Coffee Break | |
| 16:30 – 17:30 | The ACCESS Project | G. Vassal |
| TIME | TOPIC | PRESENTER |
| 17:30 – 18:45 | Business meeting – General Assembly <i>Open to members only: ITCC representatives & Local teams</i> Biology Committee report Sponsor Institution Committee report Education and Training Committee report Clinical Trials Committee report President and Treasurer reports | S. Pfister P. Kearns B. Morland B. Geoerger G. Vassal/P. Kearns |
| 20:00 | Networking Dinner <i>Open to online-registered people Venue TBC</i> | |

A G E N D A

10TH NOVEMBER

| TIME | TOPIC | PRESENTER |
|---------------|--|--|
| 8:30 – 10:40 | <p>Cancer immunotherapy for pediatric malignancies: where to go? <i>Session Chairs: B. Wulff / J. Vormoor</i></p> <p>Checkpoint inhibitors alone and combinations (MK3475 Pembrolizumab, Atezolizumab ITCC-058, Ipilimumab ITCC-034, Nivolumab + Cyclophosphamide ITCC-057 – ESMART Arm G), Nivolumab + Brentuximab, Nivolumab + Ipilimumab in CNS)</p> <p>Nivolumab + Lirilumab ITCC-057 – ESMART Arm J Nivolumab + Entinostat – INFORM2 Betting on BET combinations GD2 the new target in NB and other pediatric cancers? CAR-T019 Eliana study Zeist fellowship: Neuroblastoma vaccination trial</p> | <p>L. Marshall</p> <p>N. André C. van Tilburg NN C. Owens/P. Berlanga Bram de Wilde M. Dierselhuis</p> |
| 10:40 – 11:10 | Invited lecture: From target validation to compound design | B. Weiss |
| 11:15 – 11:30 | Coffee Break | |
| 11:30 – 13:00 | <p>DNA repair <i>Session Chairs: A. Pearson / H. Hanenberg</i></p> <p>BRCAness Replication stress What did we learn over the last years from adult trials?</p> | <p>A. Shelat F. Speleman S. Gatz</p> |
| 13:00 – 14:00 | Lunch | |
| 14:00 – 16:30 | <p>Signal transduction <i>Session Chairs: M. Zwaan / NN (biologist)</i></p> <p>Dabrafenib ITCC-037, Trametinib, Cobimetinib ITCC-055; where are BRAFi/ MEKi going? Selumetinib + Dexamethasone ITCC-063 AZD2014 + Selumetinib ITCC-057 – ESMART Arm H MEK in LGG and NF1 Afatinib ITCC-049 LOXO 101 Larotrectinib ITCC-066 Quizartinib AC220 ITCC-067 Daratumumab ITCC-070</p> | <p>D. Hargrave</p> <p>J. Vormoor P. Berlanga O. Witt K. Nysom S. Gallego M. Zwaan A. Beishuizen/M. Zwaan</p> |
| 16:30 – 17:00 | Wrap up, decisions and plan for 2018 | G. Vassal |
| 17:00 – 17:20 | Networking Coffee Break | |